Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Moxifloxacin hydrochloride
Drug ID BADD_D01502
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status Prescription; Discontinued
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D00874
MeSH ID D000077266
PubChem ID 101526
TTD Drug ID D0ZV0Z
NDC Product Code 60429-893; 58032-0131; 65862-603; 51991-943; 0065-0006; 50268-576; 49574-522; 72789-037; 48943-0025; 72789-038; 51927-0167; 0832-1410; 48943-0024; 68084-722; 13668-201; 57237-156; 66298-8507; 0781-7135; 29967-0005; 0065-4013; 63323-850; 0078-0939; 50370-0001; 0093-7387; 67457-323; 67296-1616; 50090-4100; 65862-627; 50090-4058; 55111-064; 49587-106; 40032-034; 51927-4833; 51927-0089
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H25ClFN3O4
CAS Registry Number 186826-86-8
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eosinophil count decreased13.01.06.003--Not Available
Eosinophil count increased13.01.06.004--Not Available
Eosinophilia01.02.04.001--
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Erythema23.03.06.001--Not Available
Erythema multiforme10.01.03.015; 23.03.01.003--
Euphoric mood19.04.02.006--
Eye disorder06.08.03.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Face oedema23.04.01.004; 08.01.07.003; 10.01.05.002--
Facial pain08.01.08.012--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Fungal infection11.03.05.001--Not Available
Fungal skin infection11.03.05.002; 23.09.02.001--Not Available
Gait disturbance17.02.05.016; 08.01.02.002--
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gamma-glutamyltransferase increased13.03.01.011--
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal candidiasis11.03.03.011; 07.19.02.003--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised tonic-clonic seizure17.12.01.002--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 15 Pages